ERBB2 and breast cancer: Currently, trastuzumab (TZB), an anti-HER2 monoclonal antibody, has been introduced as an effective agent to cure human HER-2-positive BC (Daniels et al., 2018), while its effectiveness can mostly be restricted by chemoresistance-associated mechanisms (Adamczyk et al., 2018).